Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 19/20 | 1.00 |
| ▸ | NQO2 | P16083 | 18/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135601 | 1.00 | MTNR1A (1.00) | MTNR1ANQO2MTNR1B | |
| SCHEMBL4687318 | 1.00 | MTNR1A (1.00) | MTNR1ANQO2MTNR1B | |
| SCHEMBL8887234 | 0.93 | MTNR1A (0.87) | MTNR1ANQO2MTNR1B | |
| SCHEMBL8886440 | 0.91 | MTNR1A (1.00) | MTNR1ANQO2MTNR1B | |
| SCHEMBL8886578 | 0.89 | MTNR1A (0.81) | MTNR1ANQO2MTNR1B | |
| SCHEMBL4689191 | 0.89 | MTNR1A (1.00) | MTNR1ANQO2MTNR1B | |
| SCHEMBL4690452 | 0.89 | MTNR1A (1.00) | MTNR1ANQO2MTNR1B | |
| SCHEMBL7956121 | 0.89 | MTNR1A (1.00) | MTNR1ANQO2MTNR1B | |
| SCHEMBL7943795 | 0.88 | MTNR1A (0.79) | MTNR1ANQO2MTNR1B | |
| SCHEMBL7950141 | 0.88 | MTNR1A (0.79) | MTNR1ANQO2MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6235789-B1 | GLANDULAR DISORDERS; SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | claimed |
| JP-9140396-A | — | — | None | — | — | JP | disclosed |
| US-20120184594-A1 | PHENYLPYRROLIDINE COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2012-07-19 | — | — | US | disclosed |
| US-20120059053-A1 | COMPOUNDS OF 2,3-DIHYDRO-BENZOFURAN | FERRER INTERNATIONAL, S.A. (ES) | 2012-03-08 | — | — | US | disclosed |
| EP-2203422-B1 | PHENYLPYRROLIDINE COMPOUNDS | FERRER INT (ES) | 2011-06-22 | — | — | EP | disclosed |
| EP-2205579-A1 | COMPOUNDS OF 2,3-DIHYDRO-BENZOFURAN | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-14 | — | — | EP | disclosed |
| EP-2203422-A1 | PHENYLPYRROLIDINE COMPOUNDS | Ferrer Internacional, S.A. (ES) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009053443-A2 | INDANE COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053441-A1 | PHENYLPYRROLIDINE COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053444-A1 | COMPOUNDS OF 2,3-DIHYDRO-BENZOFURAN | FERRER INTERNACIONAL, S.A. (ES) | 2009-04-30 | — | — | WO | disclosed |
| EP-1199304-A1 | Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders | Takeda Chemical Industries, Ltd. (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6235789-B1 | GLANDULAR DISORDERS; SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| US-6218429-B1 | TREATING MELATONIN RELATED DISORDERS (E.G. CIRCARDIAN RHYTHMS, SLEEP-AWAKE CYCLES, TIME ZONE CHANGES, SLEEP DISORDERS) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0781271-B1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-06-07 | — | — | EP | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
| EP-0781271-A1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-07-02 | — | — | EP | disclosed |
| JP-H09140396-A | PRODUCTION OF OPTICAL ACTIVATOR BY BACTERIUM | TAKEDA CHEM IND LTD | 1997-06-03 | — | — | JP | disclosed |
| WO-1996008466-A1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059053-A1 | COMPOUNDS OF 2,3-DIHYDRO-BENZOFURAN | MTNR1A, MTNR1B, CRY2 | MTNR1A 1/4885NQO2 1107/4885MTNR1B 2/4885 |
| US-20120184594-A1 | PHENYLPYRROLIDINE COMPOUNDS | MTNR1A, MTNR1B, MC4R | MTNR1A 1/4885NQO2 1798/4885MTNR1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.